Welcome to our dedicated page for CF Acquisition VII news (Ticker: CFFS), a resource for investors and traders seeking the latest updates and insights on CF Acquisition VII stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CF Acquisition VII's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CF Acquisition VII's position in the market.
CF Acquisition Corp. VII (Nasdaq: CFFSU) has priced its initial public offering at $10.00 per unit, raising $175 million. The offering consists of 17,500,000 units, each including one share of Class A common stock and one-third of a warrant, with whole warrants exercisable at $11.50 per share. Trading is set to commence on December 16, 2021, with underwriters having a 45-day option for an additional 2,625,000 units. The offering's closure is anticipated on December 20, 2021.
FAQ
What is the market cap of CF Acquisition VII (CFFS)?
